ENTERO

Entero Healthcare Solutions Share Price

 

 

Invest in Entero Healthcare Solutions with 2.65X leverage

Invest with MTF

Performance

  • Low
  • ₹1,201
  • High
  • ₹1,227
  • 52 Week Low
  • ₹944
  • 52 Week High
  • ₹1,564
  • Open Price₹1,225
  • Previous Close₹1,224
  • Volume59,848
  • 50 DMA₹1,087.39
  • 100 DMA₹1,109.25
  • 200 DMA₹1,152.46

Investment Returns

  • Over 1 Month + 21.57%
  • Over 3 Month + 9.11%
  • Over 6 Month -3.54%
  • Over 1 Year -13.62%

Smart Investing Starts Here Start SIP with Entero Healthcare Solutions for Steady Growth!

Invest Now

Entero Healthcare Solutions Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 47.7
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 5,271
  • P/B Ratio
  • 3
  • Average True Range
  • 48.16
  • EPS
  • 25.4
  • Dividend Yield
  • 0
  • MACD Signal
  • 29.46
  • RSI
  • 70.05
  • MFI
  • 82.89

Entero Healthcare Solutions Financials

Entero Healthcare Solutions Technicals

EMA & SMA

Current Price
₹1,211.30
-12.4 (-1.01%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,115.77
  • 50 Day
  • ₹1,087.39
  • 100 Day
  • ₹1,109.25
  • 200 Day
  • ₹1,152.46

Resistance and Support

1213.33 Pivot Speed
  • R3 1,251.47
  • R2 1,239.43
  • R1 1,225.37
  • S1 1,199.27
  • S2 1,187.23
  • S3 1,173.17

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Entero Healthcare Solutions is a leading supply chain and distribution company in India, specializing in pharmaceuticals, medical devices, and healthcare products. It provides end-to-end logistics services, connecting manufacturers with pharmacies, hospitals, and healthcare providers nationwide.

Entero Healthcare Solutions Ltd has an operating revenue of Rs. 5,672.82 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 5% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 200DMA and around 13% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 68 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 18 indicates it belongs to a strong industry group of Medical-Supplies and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Entero Healthcare Solutions Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-08-08 Quarterly Results
2025-05-27 Audited Results
2025-02-12 Quarterly Results
2024-11-12 Quarterly Results

Entero Healthcare Solutions F&O

Entero Healthcare Solutions Shareholding Pattern

52.42%
4.78%
0%
14.68%
9.36%
18.76%

About Entero Healthcare Solutions

  • NSE Symbol
  • ENTERO
  • BSE Symbol
  • 544122
  • Managing Director & CEO
  • Mr. Prabhat Agrawal
  • ISIN
  • INE010601016

Similar Stocks to Entero Healthcare Solutions

Entero Healthcare Solutions FAQs

Entero Healthcare Solutions share price is ₹1,211 As on 16 January, 2026 | 05:25

The Market Cap of Entero Healthcare Solutions is ₹5270.5 Cr As on 16 January, 2026 | 05:25

The P/E ratio of Entero Healthcare Solutions is 47.7 As on 16 January, 2026 | 05:25

The PB ratio of Entero Healthcare Solutions is 3 As on 16 January, 2026 | 05:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23